Skip to main content
OpenTrials

Clinical trial condition

Gastro-enteropancreatic neuroendocrine tumor

Explore clinical trials studying Gastro-enteropancreatic neuroendocrine tumor. Study availability and eligibility vary by location and protocol.

46 public trials 19 recruiting studies
Refine in advanced search Browse all conditions

Gastro-enteropancreatic neuroendocrine tumor trial results

Completed

A Study of Peptide Receptor Radionuclide Therapy (PRRT) Use in Neuroendocrine Tumor (NET) Patients in Germany

NCT07653126

Conditions
Gastro-enteropancreatic Neuroendocrine Tumor, Gastro-enteropancreatic neuroendocrine tumor, Neoplasms, +5 more
Locations
  • Novartis Investigative Site Essen, Germany
  • Novartis Investigative Site Heidelberg, Germany
  • Novartis Investigative Site München, Germany
  • Novartis Investigative Site Rostock, Germany
View Trial Details
Completed

Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs

NCT04727723

Conditions
Gastro-enteropancreatic neuroendocrine tumor, Gastroenteropancreatic Neuroendocrine Tumor, Neoplasms, +5 more
Locations
  • Novartis Investigative Site Alessandria, Italy
  • Novartis Investigative Site Bologna, Italy
  • Novartis Investigative Site Brescia, Italy
  • Novartis Investigative Site Cona, Italy
View all 18 locations
View Trial Details
Completed

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

NCT02611024

Conditions
Adenoma, Adnexal Diseases, Advanced Solid Tumors, +53 more
Locations
  • Sarcoma Oncology Center Santa Monica, California, United States
  • Massachusetts General Hospital - Boston, Massachusetts, United States
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
  • The University of Texas MD Anderson Cancer Center Houston, Texas, United States
View all 23 locations
View Trial Details
Completed

Nutrition in Gastroenteropancreatic Neuroendocrine Tumor

NCT04986085

Conditions
Gastro-enteropancreatic neuroendocrine tumor, Gastroenteropancreatic Neuroendocrine Tumor, Neoplasms, +5 more
Locations
  • Hospital Universitario Virgen de la Arrixaca El Palmar, Murcia, Spain
  • Hospital Universitario Vall d´Hebron Barcelona, Spain
  • Hospital Universitario Reina Sofia Córdoba, Spain
  • Hospital Universitario de Cabueñes Gijón, Spain
View all 16 locations
View Trial Details
Completed

Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients

NCT04524442

Conditions
Adenocarcinoma, Carcinoid Tumor, Carcinoma, +9 more
Locations
  • Istituto Europeo di Oncologia Milan, MI, Italy
  • Erasmus University Medical Center Rotterdam, Gelderland, Netherlands
  • Gammed-Centrum Diagnostyczno-Lecznicze Warsaw, Poland
  • University Hospitals Birmingham NHS Foundation Trust Birmingham, United Kingdom
View Trial Details
Completed

Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.

NCT03980925

Conditions
Gastro-enteropancreatic neuroendocrine tumor, Gastroenteropancreatic Neuroendocrine Tumor, Neoplasms, +6 more
Locations
  • Institut Català d'Oncologia Badalona Badalona, Barcelona, Spain
  • Institut Català d'Oncologia l'Hospitalet L'Hospitalet de Llobregat, Barcelona, Spain
  • Vall d'Hebron University Hospital Barcelona, Spain
  • Hospital Universitario 12 de Octubre Madrid, Spain
View Trial Details
Completed

Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs

NCT04852679

Conditions
Gastro-enteropancreatic neuroendocrine tumor, Gastroenteropancreatic Neuroendocrine Tumor
Locations
  • Cancer Hospital Chinese Academy of Sciences Beijing, Beijing Municipality, China
  • Beijing Cancer Hospital Beijing, Beijing Municipality, China
  • Peking University Third Hospital Beijing, Beijing Municipality, China
  • The First Affiliated Hospital, Sun Yat-Sen University Guangzhou, Guangdong, China
View all 14 locations
View Trial Details

Related conditions